Race-free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment.
Benjamin N SchmeusserArnold R PalaciosEric R MidenbergReza NabavizadehDattatraya H PatilRobert Donald HarveyJanetta BryksinMichael J ConnorKenneth OganMehmet A BilenViraj A MasterPublished in: Cancer (2023)
Black patients experience worse oncologic outcomes and are underrepresented in clinical trials. Kidney function, as estimated by glomerular filtration rate equations, is a factor in who can and cannot be in a clinical trial. Race is a variable in some of these equations. For Black patients, removing race from these equations leads to the calculation of lower kidney function. Lower estimated kidney function may result in more black patients being excluded from clinical trials. The inclusion of all races in clinical trials is important for offering best care to everyone and for making results from clinical trials applicable to everyone.
Keyphrases
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- prostate cancer
- peritoneal dialysis
- healthcare
- open label
- patient reported outcomes
- adipose tissue
- metabolic syndrome
- study protocol
- climate change
- double blind
- papillary thyroid
- health insurance
- lymph node metastasis
- rectal cancer